Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Pulmonary cryptococcoma in a patient with Sézary syndrome treated with alemtuzumab.

Hotz C, Ingen-Housz-Oro S, Tran Van Nhieu J, Charlier C, Foulet F, Rahmouni A, Zegai B, Duong TA, Wolkenstein P, Bagot M, Chosidow O.

Eur J Dermatol. 2011 Nov-Dec;21(6):1018-20. doi: 10.1684/ejd.2011.1538. No abstract available.

PMID:
21926045
2.

Can the level of CD52 expression on Sézary cells be used to predict the response of Sézary syndrome to alemtuzumab?

Fernandes IC, Gonçalves M, dos Anjos Teixeira M, Gonçalves C, Coutinho J, Selores M, Alves R, Lima M.

J Am Acad Dermatol. 2012 Nov;67(5):1083-5. doi: 10.1016/j.jaad.2012.05.010. No abstract available.

PMID:
23062898
3.

Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.

Bassetti M, Repetto E, Mikulska M, Miglino M, Clavio M, Gobbi M, Righi E, Viscoli C.

J Chemother. 2009 Apr;21(2):211-4.

PMID:
19423476
4.

Cutaneous cryptococcus infection due to C. albidus associated with Sézary syndrome.

Narayan S, Batta K, Colloby P, Tan CY.

Br J Dermatol. 2000 Sep;143(3):632-4.

PMID:
10971343
5.

Alemtuzumab in refractory Sézary syndrome.

Reifs CM, Salido-Vallejo R, Garnacho-Saucedo GM, Corte-Sánchez S, González-Menchen A, García-Nieto AV.

An Bras Dermatol. 2016 Sep-Oct;91(5):642-644. doi: 10.1590/abd1806-4841.20164322.

6.

Alemtuzumab treatment for Sézary syndrome: A single-center experience.

Novelli S, García-Muret P, Sierra J, Briones J.

J Dermatolog Treat. 2016;27(2):179-81. doi: 10.3109/09546634.2015.1086479. Epub 2015 Sep 25.

PMID:
26329989
7.
8.

Alemtuzumab in Sézary syndrome: efficient but not innocent.

Ure UB, Ar MC, Salihoglu A, Guner SI, Baran A, Oguz O, Ferhanoglu B.

Eur J Dermatol. 2007 Nov-Dec;17(6):525-9. Epub 2007 Oct 19.

PMID:
17951134
9.

Treatment of Sézary Syndrome With Alemtuzumab: A Series of 5 Cases and a Review of the Literature.

del Alcázar-Viladomiu E, Tuneu-Valls A, López-Pestaña A, Vidal-Manceñido MJ.

Actas Dermosifiliogr. 2015 Sep;106(7):e33-9. doi: 10.1016/j.ad.2015.02.008. Epub 2015 May 7. Review. English, Spanish.

PMID:
25960287
10.

Alemtuzumab-resistant Sézary syndrome responding to zanolimumab.

Alexandroff AB, Shpadaruk V, Bamford WM, Kennedy DB, Burd R, Dyer MJ.

Br J Haematol. 2011 Aug;154(3):419-21. doi: 10.1111/j.1365-2141.2011.08620.x. Epub 2011 Apr 12. No abstract available.

PMID:
21480857
11.

Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia.

Pitini V, Cascio A, Arrigo C, Altavilla G.

Br J Haematol. 2012 Jan;156(1):1. doi: 10.1111/j.1365-2141.2011.08802.x. Epub 2011 Jul 25. No abstract available.

PMID:
21790529
12.

Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sézary syndrome.

Jawed SI, Busam K, Wang X, Horwitz S, Querfeld C.

JAMA Dermatol. 2014 Sep;150(9):1021-3. doi: 10.1001/jamadermatol.2013.10615. No abstract available.

PMID:
25029560
13.

Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome.

Cameron ML, Bartlett JA, Gallis HA, Waskin HA.

Rev Infect Dis. 1991 Jan-Feb;13(1):64-7.

PMID:
2017634
14.

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.

Lundin J, Hagberg H, Repp R, Cavallin-Ståhl E, Fredén S, Juliusson G, Rosenblad E, Tjønnfjord G, Wiklund T, Osterborg A.

Blood. 2003 Jun 1;101(11):4267-72. Epub 2003 Jan 23.

15.

Sezary syndrome presenting with leonine facies and treated with low-dose subcutaneous alemtuzumab.

Oliveira A, Lobo I, Alves R, Lima M, Selores M.

Dermatol Online J. 2011 Nov 15;17(11):6.

16.

Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome.

Roch N, Salameire D, Gressin R, Morand P, Epaulard O, Pavese P, Brion JP, Stahl JP.

Scand J Infect Dis. 2008;40(4):343-6.

PMID:
17934981
17.

Hypoglycemia in a patient with advanced Sezary syndrome.

Anagnostis P, Vakalopoulou S, Slavakis A, Simoulidou E, Rakitzi P, Garipidou V, Harsoulis F.

Leuk Lymphoma. 2009 Feb;50(2):284-6. doi: 10.1080/10428190802582652. No abstract available.

PMID:
19160123
18.

Cutaneous cryptococcosis mimicking basal cell carcinoma in a patient with Sézary syndrome.

Töröcsik D, Gergely L, Veres I, Remenyik É, Bégány Á.

Acta Derm Venereol. 2012 May;92(3):286-7. doi: 10.2340/00015555-1326. No abstract available.

19.

A Sézary cryptogram. Disseminated cryptococcal infection.

Desar IM, Stevens WB, Verweij PE, van der Velden WJ.

Neth J Med. 2011 Jul-Aug;69(7):346, 349. No abstract available.

20.

Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).

Gautschi O, Blumenthal N, Streit M, Solenthaler M, Hunziker T, Zenhäusern R.

Eur J Haematol. 2004 Jan;72(1):61-3.

PMID:
14962265

Supplemental Content

Support Center